The following monoclonal antibody is used in senile dementia
**Core Concept**
The question is testing knowledge of monoclonal antibodies used in the treatment of senile dementia, specifically Alzheimer's disease. This involves understanding the pathophysiology of Alzheimer's disease and the role of amyloid plaques in its progression.
**Why the Correct Answer is Right**
The correct answer is a monoclonal antibody that targets amyloid beta peptides, which are central to the pathogenesis of Alzheimer's disease. By binding to amyloid beta, this monoclonal antibody helps to reduce the formation of amyloid plaques, a hallmark of Alzheimer's disease. This mechanism of action is thought to slow the progression of cognitive decline in patients with Alzheimer's disease.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it is a monoclonal antibody used in the treatment of rheumatoid arthritis, not senile dementia. It targets tumor necrosis factor-alpha (TNF-alpha), which is involved in the inflammatory process.
**Option B:** This option is incorrect because it is a monoclonal antibody used in the treatment of multiple sclerosis, not senile dementia. It targets alpha-4 integrin, which is involved in the adhesion of immune cells to the blood-brain barrier.
**Option C:** This option is incorrect because it is a monoclonal antibody used in the treatment of cancer, not senile dementia. It targets epidermal growth factor receptor (EGFR), which is involved in the proliferation of cancer cells.
**Clinical Pearl / High-Yield Fact**
It's essential to remember that monoclonal antibodies targeting amyloid beta are a new class of treatments for Alzheimer's disease, and their effectiveness in slowing cognitive decline is still being studied.
**Correct Answer:** B.